Max Colao, MBA, joined OncoVerity as Chief Executive Officer, bringing more than 30 years of biotechnology leadership expertise. His most recent role was as Chief Commercial Officer at Aurinia, where he established and guided the commercial team through launch. At Alexion, Max took on progressively senior roles, heading the US commercial operations and leading the launches of several rare disease therapies. Max also spent two decades at Amgen, in a number of senior positions, where he launched various therapies in hematology, oncology, and autoimmune disorders including Enbrel™, significantly contributing to Amgen’s transformation from small biotech to large pharma.